After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...

he would be eligible for a lump sum payment equal to one year's base salary plus target bonus, along with continued medical and dental benefits. Biogen has clarified that Godbout's appointment did ...

Also Read: Biogen Downgraded On Pipeline Setbacks And ... Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.

Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Read why I think SAGE stock is a good buy at these levels.

The approval of Calquence marks the first and only BTK inhibitor approved for the first-line treatment of MCL in the US.

The phase 3 study assessed the use of tafasitamab-cxix (Monjuvi; MorphoSys, Incyte) plus lenalidomide and rituximab (Rituxan; Genentech, Biogen) compared with placebo, lenalidomide and rituximab ...

Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform. | Neomorph is ...

Sandrock left Biogen after 23 years at the company as the ... for Friedreich's ataxia and other undisclosed diseases. On the plus side, Voyager agreed a $630 million alliance with Pfizer in ...

US biotech Atalanta Therapeutics has come out of stealth mode backed with $110m from Biogen and Roche, who have also signed separate partnerships to develop new therapies for neurological diseases ...

President Donald Trump issued executive orders late Friday reviving some of his first term’s anti-abortion policies, like ...